Jonathan Silverberg, MD, PhD, MPH @JonathanMd

Dr. Silverberg is a Professor of Dermatology at the George Washington University School of Medicine and Health Sciences Joined January 2019

Tweets

156
Followers

416
Following

52
Likes

168

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

2 months ago

Join the Revolution next month in Nashville. You can register for FREE using the code: Silverberg at checkout #PER #eczema #dermatology

0 0 1 34 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

a year ago

Join me in Music City June 6–7 for the Revolutionizing #AtopicDermatitis conference! Immerse in Nashville’s unique charm. Earn CME over two days of cutting-edge derm education. Use Silverberg at checkout for free registration bit.ly/4iN3X7a #RAD2025 #gotoper

0 0 1 161 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

a year ago

The Revolutionizing Atopic Dermatitis Conference in in Nashville, TN on June 6–7 this year! Join me and leading experts for two days of learning, networking, and AD insights. Use my code Silverberg for free registration! bit.ly/4iN3X7a #RAD2025 #AtopicDermatitis #gotoper

0 0 1 146 1

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

a year ago

Thrilled to share that Dr. Chovatiya will be joining me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN! Use my code Silverberg for free registration and save your spot now: bit.ly/41D2vwU #RAD #AtopicDermatitis #gotoper

1 2 2 309 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

a year ago

Join me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN! We will be discussing groundbreaking concepts in AD—where medicine meets Nashville’s rhythm. Use my code Silverberg for free registration: bit.ly/41D2vwU #RAD #AtopicDermatitis #gotoper

0 0 0 203 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

2 years ago

0 0 0 113 0

View Details

Revolutionizing AD @RevAtopicDerm

2 years ago

You’re invited to the December virtual update on Revolutionizing Atopic Dermatitis! Get ready for CME/CE with practical patient-centered conversations and presentations on late-breaking research. Join us on December 8: bit.ly/3Z1YMaW @JonathanMd , @RajMDPhD

0 1 1 133 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

4 years ago

Check out this study of the validity of ICD10 codes for identifying #atopicdermatitis in health services research. You can learn more about these results at the @RevAtopicDerm conference on December 11th. rdcu.be/cZv7g #eczema #dermtwitter #allergy #dermatology

0 1 2 0 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

4 years ago

New Directions in Atopic Dermatitis Management: Harnessing the Power of Social Learning to Improve Patient Outcomes medicallogix.gathered.com/invitation?ref…

0 0 1 0 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

4 years ago

Stay tuned for more programs.

@derm_ce @derm_ce

4 years ago

33) And that's it! You just earned 0.5h CE/#CME just by following this 🧵. Accredited education on Twitter! What a concept! I am @JonathanMd inviting you to FOLLOW @derm_ce for more #tweetorials in #dermatology from expert authors. #dermtwitter #FOAMed @derminterest @DermNPPA

1 0 1 0 0

0 0 0 0 0

View Details

Jonathan Silverberg, MD, PhD, MPH @JonathanMd

4 years ago

It is an exciting time in #dermatology.

@derm_ce @derm_ce

4 years ago

32) It appears that #topical application avoids the rare #toxicity seen with #systemic administration of #JAK-inhibitors. #AD is a pervasive problem in kids & adults and it's great to envision new, targeted, effective therapies!

1 0 1 0 0

0 1 2 0 0

View Details

@derm_ce @derm_ce

4 years ago

31) There is growing evidence that JAK inhibitors are efficacious in #atopic_dermatitis, #alopecia_areata, #psoriasis, & #vitiligo. Additional evidence suggests that JAK inhibition may be broadly useful in dermatology, with early reports of efficacy in several other conditions.

1 1 2 0 0

View Details

@derm_ce @derm_ce

4 years ago

29) Studies in Japanese adults with #AD of #topical #delgocitinib 0.5% ointment have been promising. See 🔓jaad.org/article/S0190-…

1 1 2 0 0

View Details

@derm_ce @derm_ce

4 years ago

25b) Significant itch reductions versus vehicle were reported within 12 hours of first application of 1.5% RUX (P < .05). Application site reactions were infrequent (<1%) and lower with RUX versus vehicle; none were clinically significant.

1 1 1 0 0

View Details

@derm_ce @derm_ce

4 years ago

24a) Indeed, there are 2⃣: Topical #Ruxolitinib Evaluation in #Atopic_Dermatitis Study 1 (NCT03745638) & Study 2 (NCT03745651) #TRuE_AD enrolled patients aged ≥12 yrs with AD for ≥2 yrs, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area.

4 years ago

10a) Thus #JAK inhibition can block the effects of multiple cytokines that are major players in #AD pathophysiology & ⬇️symptomatology. As per previous expert tweetorials from @DrStevenTChen @itchdoctor @Aller_MD (still available for CE/#CME credit at academiccme.com/dermatology-tw…)...

1 1 2 0 0

View Details

@derm_ce @derm_ce

4 years ago

9) The #JAK-#STAT signaling pathway mediates effects of several key #cytokines on immune cells, keratinocytes, and peripheral sensory neurons that lead to inflammation and itch, including IL-4, IL-5, IL-13, IL31, IL-22, and TSLP See pubmed.ncbi.nlm.nih.gov/34437922/.